Meetings of Interest

DCBS 2023 Annual Public Hearing on Prescription Drug Prices

Public hearing on prescription drug prices

The hearing will be held virtually on Zoom.


Thursday, dec 7, 2023

1:30 pm to 4:00 pm

Oregon Pharmacy & Therapeutics Committee

Final documents for the December 7th Pharmacy & Therapeutics Committee meeting have been posted to:
This meeting will be conducted by teleconference and webinar; the access information will be made available on the website.
Final Documents: To submit written comments or to sign up to provide public comment during the P&T meeting, please use this email address and be sure to include a completed conflict of interest form:
P&T committee members will consider written public comments submitted based on final documents and upon submission of a completed Conflict of Interest form:
Please submit COI form at least 24 hours prior to the start of a meeting. Policies for public comment can be found here:

Health Evidence Review Commission (HERC) Listening Session

The Health Evidence Review Commission (HERC) staff will hold a listening session for ideas and concerns related to coverage of health services on the Prioritized List on December 12, 2023, 9:00-10:30 am.

Our priority for this meeting is to hear from Oregon Health Plan (OHP) members, their caregivers and providers.

To suggest a topic for discussion, please register by Noon Pacific time on November 27, 2023 at:
Staff may contact you to discuss your suggested topic
To attend as a “listen-only” participant, please self-register for the webinar at:
Please mark your calendars
Staff will be available to hear your concerns or suggested topics for HERC consideration and answer questions. HERC members will not be present, and no decisions or policy changes will be approved at this time.

Questions? Please email

Tuesday, Dec 12, 2023

9:00 am to 10:30 am

Prescription Drug Affordability Board (PDAB)

Monthly Meeting

Register Here

About the PDAB

Senate Bill 844 created the Prescription Drug Affordability Board (PDAB) to evaluate the cost of prescription drugs and determine whether they present an affordability challenge for consumers and health systems in Oregon. PDAB’s review will inform rulemaking criteria for evaluating drugs, including health inequities in diverse communities, the number of Oregon residents prescribed the drug, the price of the drug in Oregon, and other criteria. The board has studied the prescription drug distribution and payment system in Oregon and the generic drug market and provided recommendations to the Legislature. The Oregon Legislature acted on the board recommendations by passing Senate Bill 192 in June 2023. The board statutory authority is ORS 646A.693-697

Wednesday, Dec 13, 2023

9:30 am